Published in Rheumatology (Oxford) on January 06, 2004
RCT of Methotrexate Added to Treatment As Usual in Schizophrenia (RECOVERY) | NCT02074319
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Current treatment of ulcerative colitis. World J Gastroenterol (2011) 1.17
The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther (2009) 1.15
Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf (2009) 0.99
Cardiovascular disease in rheumatoid arthritis: a systematic literature review in latin america. Arthritis (2012) 0.89
Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol Med (2012) 0.84
The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity. Open Rheumatol J (2011) 0.82
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol (2016) 0.80
Methotrexate Is a JAK/STAT Pathway Inhibitor. PLoS One (2015) 0.79
Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literature. Multidiscip Respir Med (2010) 0.79
A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab (2012) 0.78
The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol (2007) 0.78
Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. Lupus (2010) 0.76
Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol (2010) 0.75
Methotrexate and folic acid: what is the optimal combination? Rheumatology (Oxford) (2004) 0.75
Treatment of acute lymphoblastic leukemia from traditional chinese medicine. Evid Based Complement Alternat Med (2014) 0.75
Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study). Arthritis Res Ther (2015) 0.75
Chronic administration of oral trimethoprim-sulfamethoxazole for acne vulgaris. J Clin Aesthet Dermatol (2011) 0.75
Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients. Biomark Res (2015) 0.75
Circulating DNA in rheumatoid arthritis: pathological changes and association with clinically used serological markers. Arthritis Res Ther (2017) 0.75
Education for arthritis patients: a community pharmacy based pilot project. Pharm Pract (Granada) (2009) 0.75
Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol (2017) 0.75
Folic acid supplementation during methotrexate treatment: nonsense? Rheumatology (Oxford) (2005) 0.75
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega (2017) 0.75
[Reducing toxicity of methotrexate with folic acid]. Z Rheumatol (2005) 0.75
Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med (1995) 5.73
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
Controlled trial prednisolone in acute polyneuropathy. Lancet (1978) 3.71
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med (1991) 2.92
Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation (1990) 2.74
A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry (1988) 2.63
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry (1988) 2.56
Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry (1997) 2.52
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
Nosocomial multiply resistant Klebsiella pneumoniae: epidemiology of an outbreak of apparent index case origin. Antimicrob Agents Chemother (1979) 2.13
Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry (1998) 2.07
The psychometric properties of clinical rating scales used in multiple sclerosis. Brain (1999) 2.06
The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler (1999) 2.02
Imaging in transient regional osteoporosis. Br J Rheumatol (1997) 2.01
Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med (1991) 2.01
Relapsing polychondritis. Three cases with a clinico-pathological study and literature review. Q J Med (1972) 1.87
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med (1993) 1.67
Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother (1991) 1.67
Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2000) 1.62
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int (2000) 1.62
Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol (1995) 1.60
Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med (1990) 1.57
Trigeminal sensory neuropathy. A study of 22 cases. Brain (1987) 1.56
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
Prospective study of the usefulness of sural nerve biopsy. J Neurol Neurosurg Psychiatry (2000) 1.50
Guillain-Barré syndrome after treatment with streptokinase. BMJ (1992) 1.48
A case of fatal peri-partum cardiomyopathy. Br Heart J (1970) 1.46
Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet (1984) 1.43
Acute inflammatory polyneuropathy. Br J Hosp Med (1978) 1.42
Nosocomial febrile illnesses in patients on an internal medicine service. Arch Intern Med (1989) 1.41
Vasculitic neuropathy in association with chronic graft-versus-host disease. J Neurol Sci (1999) 1.41
Clinical scales for multiple sclerosis. J Neurol Sci (1996) 1.39
Intravenous IgG in Guillain-Barré syndrome. BMJ (1996) 1.38
Chronic relapsing axonal neuropathy: a first case report. Ann Neurol (1995) 1.38
The effects of methotrexate on pregnancy, fertility and lactation. QJM (1999) 1.36
Prognosis in Guillain-Barré syndrome. Lancet (1985) 1.33
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain (2001) 1.32
Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. J Cell Biol (1991) 1.30
Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol (1999) 1.28
Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry (1999) 1.27
The course of patients with suspected myocardial infarction. The identification of low-risk patients for early transfer from intensive care. N Engl J Med (1980) 1.27
Plasma exchange for Guillain-Barré syndrome. Br Med J (Clin Res Ed) (1985) 1.24
The susceptibility of rat strains to experimental allergic encephalomyelitis. Immunology (1973) 1.23
Identification of the neuritogen for experimental allergic neuritis. Nature (1979) 1.21
Reliability of distance estimation by doctors and patients: cross sectional study. BMJ (1998) 1.21
Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev (2002) 1.20
Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol (1991) 1.19
Multiple mononeuropathy as the initial presentation of systemic lupus erythematosus--nerve biopsy and response to plasma exchange. J Neurol (1982) 1.19
Ciliary neurotrophic factor. J Neurobiol (1994) 1.17
Lymphocyte subpopulations and suppressor cell activity in acute polyradiculoneuritis (Guillain-Barré syndrome). Clin Exp Immunol (1983) 1.17
An assessment of disability rating scales used in multiple sclerosis. Arch Neurol (1991) 1.16
Experimental allergic neuritis in the Lewis rat: characterization of the activity of peripheral myelin and its major basic protein,P2. Brain Res (1980) 1.14
Mixed or immune complex cryoglobulinaemia and neuropathy. J Neurol Neurosurg Psychiatry (1974) 1.13
Acute necrotic myelopathy with pulmonary tuberculosis. Brain (1977) 1.12
Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab (1998) 1.11
A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review. Brain (1991) 1.11
MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry (1993) 1.09
Microangiopathy of vasa nervorum in dysglobulinemic neuropathy. Ann Neurol (1984) 1.07
Sterilization of instruments in isolated hospitals. Trop Doct (1982) 1.07
Prospects for the treatment of multiple sclerosis. J R Soc Med (1991) 1.07
Identification of patients at risk of arrhythmia in the Guillain-Barré syndrome. Q J Med (1988) 1.06
T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology (1990) 1.06
Intellectual impairment in neurofibromatosis 1. J Neurol Sci (1996) 1.04
A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol (1996) 1.03
HLA-B27 subtypes in the spondarthropathies. Clin Exp Immunol (1993) 1.03
The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol (1991) 1.02
HLA antigens in the Guillain-Barré syndrome. J Neuroimmunol (1988) 1.01
Protection of rats from experimental allergic encephalomyelitis with antiserum to guinea-pig spinal cord. Immunology (1974) 1.01
Persistence of Epstein-Barr virus in salivary gland biopsies from healthy individuals and patients with Sjögren's syndrome. Clin Exp Immunol (1989) 1.01
HLA antigens in Guillain-Barré syndrome. Lancet (1977) 1.00
Immunological mechanisms of demyelination. J R Soc Med (1992) 0.98
Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. Ther Apher (1997) 0.98
Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev (2001) 0.98
Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol (2000) 0.97
Scale development and Guy's Neurological Disability Scale. J Neurol (1999) 0.97
A prospective study of acute idiopathic neuropathy. III. Immunological studies. J Neurol Neurosurg Psychiatry (1988) 0.97
Optic neuritis following chickenpox in adults. J Neurol (1986) 0.97
Immune responses in experimental allergic neuritis. J Neurol Neurosurg Psychiatry (1981) 0.96
The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. Am Heart J (1992) 0.96
Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (1999) 0.96
HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol (1995) 0.95
Campylobacter jejuni and Guillain-Barré syndrome. Q J Med (1993) 0.95
HLA antigens in chronic relapsing idiopathic inflammatory polyneuropathy. J Neurol Neurosurg Psychiatry (1979) 0.94
The response of motoneurons to neurotrophins. Neurochem Res (1996) 0.94
Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol (1997) 0.92
Guillain-Barré syndrome after varicella-zoster infection. Report of two cases. J Neurol (1987) 0.92
P0 myelin protein produces experimental allergic neuritis in Lewis rats. J Neurol Sci (1987) 0.92
Spontaneous and experimental neuritis and the distribution of the myelin protein P2 in the nervous system. J Neurochem (1984) 0.92
Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain (1998) 0.91
Fibroblast growth factor-5 promotes differentiation of cultured rat septal cholinergic and raphe serotonergic neurons: comparison with the effects of neurotrophins. Eur J Neurosci (1994) 0.90
The distribution and functional properties of dendritic cells in patients with seronegative arthritis. Clin Exp Immunol (1991) 0.90
The myosin molecule--charge response to nucleotide binding. Biochim Biophys Acta (1993) 0.90
A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain (1997) 0.89
The Ancillary Services Review Program in Massachusetts. Experience of the 1982 pilot project. JAMA (1984) 0.89
Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol (1995) 0.89